NCT04793958

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Trial number:: NCT04793958

Trial phase:: 3

Study type:: Targeted therapy, Biomarker

Overall status:: Recruiting

Study start date

March, 2021

Scientific title

A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy

Summary

Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

Inclusion criteria

Exclusion criteria

Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue.Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment.

Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510).Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab). Active brain metastasis

Study design

Primary purpose: Treatment, Allocation: Randomized, Intervention model: Parallel Assignment, Masking: None (Open Label),

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Study start date

Scientific title

Summary

Study design

Conditions

Other study ID numbers

Choose trial site (64)